Patents Assigned to HEART METABOLICS LIMITED
-
Patent number: 9468634Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure, as well as to a method for treating heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said heart failure. The invention further relates to a treatment programme for treating heart failure, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating heart failure or the symptoms thereof.Type: GrantFiled: March 15, 2013Date of Patent: October 18, 2016Assignee: Heart Metabolics LimitedInventors: Houman Ashrafian, Michael Paul Frenneaux
-
Patent number: 9457017Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure, as well as to a method for treating heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said heart failure. The invention further relates to a treatment program for treating heart failure, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating heart failure or the symptoms thereof.Type: GrantFiled: March 15, 2013Date of Patent: October 4, 2016Assignee: Heart Metabolics LimitedInventors: Houman Ashrafian, Michael Paul Frenneaux
-
Patent number: 8697677Abstract: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin.Type: GrantFiled: March 15, 2013Date of Patent: April 15, 2014Assignee: Heart Metabolics LimitedInventor: Michael Paul Frenneaux
-
Publication number: 20130331321Abstract: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin.Type: ApplicationFiled: March 15, 2013Publication date: December 12, 2013Applicant: HEART METABOLICS LIMITEDInventor: HEART METABOLICS LIMITED
-
Publication number: 20130224118Abstract: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin.Type: ApplicationFiled: March 15, 2013Publication date: August 29, 2013Applicant: HEART METABOLICS LIMITEDInventor: Heart Metabolics Limited
-
Publication number: 20130210719Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure, as well as to a method for treating heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said heart failure. The invention further relates to a treatment programme for treating heart failure, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating heart failure or the symptoms thereof.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: HEART METABOLICS LIMITEDInventor: Heart Metabolics Limited
-
Publication number: 20130210720Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure, as well as to a method for treating heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said heart failure. The invention further relates to a treatment programme for treating heart failure, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating heart failure or the symptoms thereof.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: HEART METABOLICS LIMITEDInventor: HEART METABOLICS LIMITED
-
Patent number: 8470806Abstract: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure may be non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin.Type: GrantFiled: September 23, 2011Date of Patent: June 25, 2013Assignee: Heart Metabolics LimitedInventor: Michael Paul Frenneaux
-
Patent number: 8440697Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of HfnEF, as well as to a method of treating HfnEF, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said HFnEF. The invention further relates to a treatment program for treating HFnEF, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HFnEF or the symptoms thereof.Type: GrantFiled: May 21, 2010Date of Patent: May 14, 2013Assignee: Heart Metabolics LimitedInventors: Houman Ashrafian, Michael P. Frenneaux
-
Publication number: 20120122925Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of hypertrophic cardiomyopathy, as well as to a method of treating HCM, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said HCM. The invention further relates to a treatment programme for treating HCM, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HCM or the symptoms thereof.Type: ApplicationFiled: May 11, 2010Publication date: May 17, 2012Applicant: HEART METABOLICS LIMITEDInventors: Houman Ashrafian, Michael Paul Frenneaux
-
Publication number: 20120101128Abstract: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure may be non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin.Type: ApplicationFiled: September 23, 2011Publication date: April 26, 2012Applicant: HEART METABOLICS LIMITEDInventor: Michael Paul Frenneaux
-
Publication number: 20100331364Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of HfnEF, as well as to a method of treating HfnEF, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said HFnEF. The invention further relates to a treatment programme for treating HFnEF, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating HFnEF or the symptoms thereof.Type: ApplicationFiled: May 21, 2010Publication date: December 30, 2010Applicant: HEART METABOLICS LIMITEDInventors: Houman Ashrafian, Michael P. Frenneaux
-
Publication number: 20070275997Abstract: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure may be non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin.Type: ApplicationFiled: September 7, 2004Publication date: November 29, 2007Applicant: HEART METABOLICS LIMITEDInventor: Michael Frenneaux